<DOC>
	<DOCNO>NCT02432872</DOCNO>
	<brief_summary>The purpose study determine whether escalation dosage Daunorubicin cytarabine effective safety treatment old adult Chinese acute myeloid leukemia（AML） patient age 55 65 year .</brief_summary>
	<brief_title>Treatment Older Adult Acute Myeloid Leukemia Patients Aged 55 65 Years</brief_title>
	<detailed_description>DA 3+7 regimen standard therapy AML treatment.Escalated dosage daunorubicin induction therapy report effective result rapid response high response rate conventional dose , without additional toxic effect elderly AML patient 60 65 years.Higher Overall survival rate Event-free survival rate obtain escalate group compare conventional dose . We wonder Chinese old AML patient benefit escalated induction regimen . High dose cytarabine AML consolidation report improve survival elderly AML patient conventional dose，but determine Chinese old adult AML patient .</detailed_description>
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Leukemia , Myeloid</mesh_term>
	<mesh_term>Leukemia , Myeloid , Acute</mesh_term>
	<mesh_term>Cytarabine</mesh_term>
	<mesh_term>Daunorubicin</mesh_term>
	<criteria>primary AML（except APL patients） ; ECOG PS:02 AML patient already receive induction treatment , matter outcome ; Treatmentrelated AML ; Active cancer patient 's condition need treat ; The one serious infectious diseases（eg.uncontrolled tuberculosis invasive pulmonary aspergillosis） Active heart disease .</criteria>
	<gender>All</gender>
	<minimum_age>55 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>May 2016</verification_date>
</DOC>